Genome sequencing studies of nonhuman primate (NHP) pedigree and population samples are discovering variants on a large and rapidly growing scale. These studies are increasing the utility of several NHP species as model systems for human disease. In particular, by identifying homozygous protein truncating variants (hPTVs) in genes hypothesized to play a role in causing human diseases, it may be possible to elucidate mechanisms for the phenotypic impact of such variants through investigations that are infeasible in humans. The Caribbean vervet (Chlorocebus aethiops sabaeus) is uniquely valuable for this purpose, as the dramatic expansion of its population following severe bottlenecks has enabled PTVs that passed through the bottleneck to attain a relatively high frequency. Using whole genome sequence (WGS) data from 719 monkeys of the Vervet Research Colony (VRC) extended pedigree, we found 2,802 protein-truncating alleles in 1,747 protein-coding genes present in homozygous state in at least one monkey. Polymorphic sites for 923 SNV hPTVs were also observed in natural Caribbean populations from which the VRC descends. The vervet genome browser (VGB) includes information on these PTVs, together with a catalog of phenotypes and biological samples available for monkeys who carry them. We describe initial explorations of the possible impact of vervet PTVs on early infant mortality.
INTRODUCTION
The difficulty in determining whether specific variants are deleterious, and in identifying the phenotypic effect of such variants, are critical limitations to the utility of whole exome or whole genome sequencing within clinical medicine. Here we describe a strategy to aid this determination, through examination of protein truncating variants (PTVs) that were initially identified in humans but that occur naturally in populations of the Caribbean vervet nonhuman primate (NHP) model. Of the putatively deleterious variant types, PTVs have been the most extensively investigated, because their potential functional impact is most obvious and because their association with specific phenotypes can help to reveal casual pathways of disease. In humans, much of what is known about the biology of PTVs derives from studies of populations whose demographic histories increase the likelihood of identifying homozygous carriers of such variants. Examples include population isolates with extensive consanguinities, such as the Old Order Amish (Strauss and Puffenberger 2009) or that have experienced recent rapid expansion from extreme bottlenecks, such as Finland (Lim et al. 2014; Locke et al. 2019 ). The advent of sequencing studies of large human cohorts has generated a robust pipeline of PTV discovery, which has led to the identification of a number of large-effect associations to diseases or diseaserelated traits (Dewey et al. 2016) . However, most of the PTVs identified through such studies to date are present in the genomes of apparently healthy individuals (MacArthur et al. 2012 ), suggesting that their phenotypic impact, if any, may not be obvious (Rivas et al. 2015; Jagannathan and Bradley 2016) .
Investigations in model systems have traditionally provided an avenue to help distinguish between damaging and benign PTVs in the ever-expanding catalogs of publicly accessible sequence variant databases (e.g. ExAC (Lek et al. 2016) , Database of Essential Genes (Luo et al. 2014 ), ClinVar (Landrum et al. 2016 ) and OMIM (https://omim.org). However the genetic, morphological, and physiological distance from humans of the most widely used model systems has often limited the utility of this strategy. Several NHP research colonies are comprised of old world monkeys (OWM) that are the most closely related to humans of all model systems, are managed in well-established pedigrees and are characterized by relatively limited interindividual variability in environmental exposures such as diet. Such colonies offer an opportunity to study PTV effects in homozygous or heterozygous states with a degree of control over experimental variables that far exceeds that of human studies that have examined PTV effects (Lim et al. 2014; Sulem et al. 2015; Narasimhan et al. 2016a Narasimhan et al. , 2016b .
To our knowledge no studies have attempted to associate human PTVs, broadly, to observed NHP phenotypes, and there is little information, to date, on the extent of overlap between human and NHP PTVs . Among captive rhesus macaques, two studies have shown various degree of shared PTVs with human, depending on the types of variant filters deployed (Xue et al. 2016; Bimber et al. 2017) . In six great ape populations, a range of PTVs was reported, with a strict focus on the stop gain classification (de Valles-Ibáñez et al. 2016) . Sundaram et al. developed a deep neural learning algorithm to identify pathogenic variants in patients affected with rare diseases of unknown etiology, based on the prevalence of the variants in NHPs (Sundaram et al. 2018) . By training this neural network on six NHP species (including chimpanzee), they generated a database of 70 million missense variants that they proposed warranted further interpretation and validation. While great apes are evolutionarily closer to humans than OWM, experimental (or even observational) studies of the phenotypic impact of PTVs are not generally possible.
We previously generated a robust collection of SNVs for the vervet, a species used as a model for several human diseases ) and a tissue gene expression and eQTL catalog, thus far not available from other NHPs . We describe here a new vervet genetic resource, a genome browser that catalogs genome-wide PTVs from 719 monkeys from the Vervet Research Colony (VRC) extended pedigree. For each of these monkeys, the browser provides phenotypic data and an inventory of biological samples that are available to the community.
RESULTS

Protein-coding sequence variation
We have previously described the design of the studies that generated WGS data from both the VRC pedigree and from vervet populations in Africa and the Caribbean, including sampling and sequencing Svardal et al. 2017) . To recover variation in the extended vervet exome, defined as gene transcript exons expanded by +/-50 bp and padded by 1000-bp gene flanks, we undertook a two-step process of variant calling, phasing, and imputation in the 719 VRC WGS monkeys. This process uncovered 1,051,886 single nucleotide variants (SNVs) and 241,648 short indels (Table 1) . Although most of the discovered variant sites are biallelic, 6% of sites harbor more than one alternative allele. which is a fast genome annotation viewer (Buels et al. 2016) . This browser allows a user to view objects such as genes and variants in their genomic context. The major view presents several tracks including NCBI RefSeq, ENSEMBL 1.82 and 1.91 gene annotation, PTV information, Supplementary Table 2 .
Segregating PTVs
The segregating vervet PTVs that we discovered, especially those present in a homozygous state, represent natural candidates for analyses aimed at identifying the phenotypic impact of vervet genetic variants. Out of 9,574 discovered PTVs in protein-coding genes, 2,802 alleles in 1,747 genes are present in a homozygous state in at least one vervet. Approximately 73% (2,047) occur in homozygous form in < 10% of all sequenced vervets, however the remaining 27% are relatively common and exhibit a broad range of frequencies in the VRC population. There are 1,502 PTVs with at least one homozygous alternative carrier in 1,133
protein-coding genes with a known human ortholog ( Supplementary Table 1 ). Also, compound heterozygotes that occur when single alleles of two different PTVs reside on different haplotypes of the same gene are found in 1,837 vervet genes harboring more than one PTV. Supplementary   Table 3 contains individual genotypes and quality information for 2,802 homozygous PTVs in 133 currently living sequenced monkeys.
Among rare PTVs, we observed numerous genes implicated in risk for human diseases: 
Expression of genes with homozygous PTVs
An earlier study reported a catalog of eQTL in vervets based on gene expression analysis in seven tissues of 58 sequenced VRC monkeys 
Homozygous PTV to phenotype association
As with all NHPs, there is currently no systematic catalog of extreme phenotypes in which to evaluate the impact of PTVs in vervet monkeys. Within the VRC early infant mortality is recorded. We hypothesized that hPTVs might play a role in this outcome (Lord et al. 2019) and found 29 homozygous and 5 compound heterozygotes that were present only in the 24 female monkeys with high rates of early infant mortality (high EIM monkeys, see Methods; Table 4 , Supplementary Table 5 ). All such variants were present in a single monkey, except for a homozygous Trp159Ter stop-gain mutation in the ARPC3 gene seen in two high EIM monkeys. Tables 6 and 7) . Two genes without annotations are said to be involved in protein-protein interactions with high EIM-related genes:
THNSL2 with ARPC3 (MINT, IntAct) and POLR2A (STRING), SLC25A36 with SLC13A5 (STRING). Table 8 ). Among human or model organisms some candidate genes have been implicated in the same or related phenotypes. This is the case, for example, with respect to WDR17 in cataract disease (Stöhr et al. 2002; Geisert et al. 2009 ) or BID in the human "cat eye syndrome", characterized by congenital malformations and deformations (Footz et al. 2001) , and in similar mouse organ morphology phenotypes (MGI:2158671). In other examples, a paralog of a vervet gene has been involved in a related phenotype, such as, TULP1 which is associated with hepatic Mallory bodies or SERPIN family members which are implicated in cardio-related and multiple organ and bone morphology abnormality phenotypes ( Supplementary Table 8 ).
Human disease mutations in vervets
We also analyzed human pathogenic missense and stop-gain mutations from ClinVar that map to polymorphic sites in orthologous vervet genes (see Methods) and found 6 missense mutations for which phenotypes observed in vervets harboring alternative allele(s) can be related to clinical features reported in human patients (Table 5 ). In three cases (PRSS1 p.Ala16Val, hereditary pancreatitis; TRIM32 p.Pro130Ser Bardet-Biedl syndrome; ACTB p.Glu117Lys
Baraitser-Winter syndrome) the human pathogenic allele matches the vervet alternative allele.
Although the matched human alleles in three separate vervet genes are known to be highly penetrant in human, we only see related phenotypes in some vervets. The lack of manifestation in other vervets with a predicted penetrant disease allele may be due to the lack of systematic phenotyping of VRC monkeys, or because some of them did not reach the age when the symptoms are observed. It is also possible that this observation reflects variable penetrance resulting from the modulatory effect of cis-regulation (Castel et al. 2018 ). protein-coding genes that are present in at least one vervet, and reporting the specific monkeys carrying these alleles, we offer the scientific community a starting point for a wide range of further possible studies.
Our initial efforts to relate these PTVs to human phenotypes illustrate these opportunities.
We find examples of vervets harboring alternative PTVs that possess clinical features reported in human patients, such as pancreatitis, Bardet-Biedl, and Baraitser-Winter syndromes. For other cases, although the PTVs appear highly penetrant in human, we don't see comparable phenotypes, motivating research focused on explaining these apparent dichotomies.
Our most extensive evaluation of PTV related vervet phenotypes focused on recurrent early infant mortality. In comparative studies there is often inconclusive evidence for the genetic causes of early infant mortality or miscarriage; for example, homozygous ARPC3 knockout mice develop only to the blastocyst stage (MGI:1928375), suggesting a higher level of tolerance for such mutations in the vervet. Another promising candidate mutation, occurring in one female vervet for which seven consecutive births resulted in early deaths, was a high-quality splice site variant in hemogloblin, HBD. Interestingly, genes that when disrupted are shown to alter blood homeostasis, such as in the thrombophilia condition, are the most popular clinically tested polymorphisms for recurrent miscarriage. Further characterization of the genomes of deceased infants and their mothers will be necessary to close our gaps in understanding the genetic predisposition to miscarriage.
The vervet resource described here is complementary to those generated in other NHP models. Recent sequencing surveys of research colony rhesus macaques have similarly revealed many PTVs that in some cases match human PTVs with relevant clinical data (Xue et al. 2016; Bimber et al. 2017) . While in that study, no macaque phenotypes were exploited to correlate to observed phenotypes in human, there is potential to do so in the future. For instance, a rhesus macaque PTV is predicted for FAM120B, a gene linked to type I diabetes.
This study provides for the first time, a near-complete survey of variants predicted to disrupt protein-coding within an NHP that has experienced population bottlenecks akin to some human populations. We have catalogued human pathogenic missense and stop-gain mutations from ClinVar (Landrum et al. 2016 ) that map to polymorphic sites in orthologous vervet genes.
We further identified instances in which the alternative allele at such vervet sites is a missense mutation that could potentially contribute to phenotypes with features similar to those observed in human patients. In the future, more extensive searches of human databases that continue to expand the catalog of PTVs, will surely increase the number of vervet PTVs warranting further study.
METHODS
Vervet genes
We constructed a comprehensive vervet gene set by merging gene transcripts from NCBI Chlorocebus sabaeus Annotation Release 100 (Pruitt et al. 2012) Vervet protein-coding genes with assigned human orthologs were characterized by recently reported pLI values that reflect probability of a gene of being loss-of-function intolerant (Lek et al. 2016 ). The analysis of 60,706 high-quality human exome sequences identified 3,230 human genes with pLI values above 0.9 reflecting near-complete depletion of predicted PTV variants (Lek et al. 2016 ). Such PTV-intolerant genes include virtually all known severe haploinsufficient human disease genes; almost 80% of them have no associated disease phenotype, suggesting undiscovered severe dominant disease genes or genes in which loss of a single copy results in embryonic lethality. Using the known orthologous relationship reflected in the gene names, respective human pLI values were assigned to 15,875 vervet genes out of total 20,080 protein-coding genes with detected sequence variants. Of these, 3,123 genes have pLI>=0.9 (constrained genes) and are thus expected to be more PTV intolerant.
Phenotype associations for human and mouse orthologs of vervet genes were derived from four sources: Mammalian Phenotype Ontology section of MGI resource (Mouse Genome Informatics) (Bult et al. 2016) , Human Phenotype Ontology (Köhler et al. 2014) , NCBI ClinVar (Landrum et al. 2016 ) and OMIM (https://omim.org). The meta-list contains gene-phenotype associations for 10,344 human genes; 4,866 genes of this list have at least one annotation related to early infant mortality (EIM): "embryo", "abnormal reproductive system physiology", "abnormal survival" sections of the phenotype tree for Mammalian Phenotype Ontology, "abnormality of prenatal development or birth", "neonatal death", "stillbirth" for human sources:
Human Phenotype Ontology, OMIM and ClinVar.
Protein-protein interactions (PPI) were assessed using the meta-base of STRING (von Mering et al. 2005 ) and I2D database (Brown and Jurisica 2005) which in turn integrates IntAct, BioGrid, and Mint databases.
Variant calling and refinement
The BAM files used to call all variant types among the VRC monkeys were as described earlier . variants with quality QUAL>=20 were lifted over to the Chlorocebus sabaeus 1.1 genome assembly using BLAT (Kent 2002 Figure 2 .
Genotype phasing and imputation
Genotype phasing and imputation was performed with BEAGLE 4.0 (r1398) software Browning 2007, 2009) At the second step, the 620 LC samples were processed in a similar way with 99 samples above used as reference haplotypes. Burn-in, phasing and imputation iteration parameters were set to 5, 20 and 5, respectively. In order to make computations feasible in terms of memory and running time requirements, chromosomes were split into chunks of 3,000 variants overlapping by 500 variants. After completion, consequent overlapping chunks in each sample were "stitched"
to form chromosome-wide haplotypes. In the resulting dataset, each genotype was assigned GATK-reported quality of initial genotype (GQ in the range from 0 to 99) and alternative allele dosage DS reported by BEAGLE (DS in the range from 0 to 2). There were three major types of genotypes in the resulting output dataset: (a) called with low quality (GQ<10), set to undefined and imputed; (b) called with intermediate quality (10<=GQ<20) and (c) high quality (GQ>=20).
Based on the evaluation of imputation quality (see below), imputed homozygotes genotypes either located at multiallelic sites or assigned dosage parameter in the range 0.1 to 1.9 at biallelic sites were set to undefined because of their low quality. Few genotypes causing Mendelian errors were set to undefined. Sites without homozygous reference alleles were also discarded, leaving in total 896,689,346 genotypes (6.9% of them undefined) at 1,243,738 sites.
Estimation of imputation quality
To estimate genotype imputation quality, we performed the following test: 10,000 randomly chosen high-quality genotypes (GQ>=50) from chromosomes 6 and 9 in LC samples were set to undefined and imputed along with the other undefined genotypes. Since the overall number of genotypes in the 620 LC samples is approximately 80.5 mln, the additional 10,000 undefined genotypes should not affect the overall imputation quality but instead can be used to measure it. Among the randomly selected genotypes, 3,500 were homozygous and 6,500 We considered PTVs that have at least one of 58 animals homozygous for the alternative allele and filtered out genes on sex chomosomes, genes with a mean count of less than 1 across all samples, as well as genes detected in fewer than 10% of samples (see Methods in ). An association test was not performed if expression was constant, or if all animals were of one genotype. Finally, this procedure gave 8,683 tested PTV-tissue combinations for 1,518 PTVs in 1,236 genes (Supplementary Table 4 ). The stringent set included 3,918 tests for 697
PTVs for which at least three homozygous alternative and three homozygous reference genotypes are high quality genotypes individually (GATK GQ≥20) or belong to runs of homozygosity.
High early infant mortality and other phenotypes
Among the 719 sequenced VRC monkeys, 272 were females with at least three birth events, for whom there were a total of 1,862 birth events. Of the 272 females with at least 3 births events, we identified 24 females with higher than normal rates of infant mortality (EIM):
either infants that were born live and died during the first month of life or were never seen alive due to stillbirths or miscarriage. Using this number, we estimated the overall rate of early infant mortality in VRC as 0.323. Based on the overall EIM rate, we calculated the binomial probability P of at least k deaths out of N total births for each female monkey and identified 18 animals with high EIM rate as P<0.05.
Various medical and life trait phenotypes have been reported for single or multiple VRC monkeys, for example, cataract (1 monkey), amyloidosis (3 monkeys), arteriosclerosis (3), arthritis (39), chronic renal disease (27), morphological malformations (3), obesity (62). For the complete list of vervets and phenotypes see Supplementary Table 9 .
Human disease mutations in vervets
We extracted 3,485 sequences of human proteins harboring missense and stop-gain disease mutations annotated as "Pathogenic" in ClinVar and aligned them to all available vervet protein sequences. Alignments with gaps or pairwise identity below 80% were removed, resulting in 22,664 human mutations in 2,810 human proteins. Of these mutations, 67 human mutations mapped to polymorphic vervet sites with missense or stop-gain variants. We kept only variants where reference or both amino acids match, accounting for reported mutation inheritance mode (recessive or dominant). If inheritance mode was not specified, autosomal recessive was assumed. This procedure gave 33 variants that were analyzed using available vervet disease phenotypes and OMIM and Human Phenotype Ontology (Köhler et al. 2014) information. We found 12 mutations where phenotypes observed in vervets harboring alternative allele(s) could be related to clinical features reported in human patients; six instances where human stop-gain variants corresponded to vervet missense variants were discarded, leaving six variants reported (Table 5) .
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